Reviewer’s report

Title: A randomized, double-blind, positive-controlled, prospective, dose-response clinical study to evaluate the efficacy and tolerability of an aqueous extract of Terminalia bellerica in lowering uric acid and creatinine levels in chronic kidney disease subjects with hyperuricemia.

Version: 2 Date: 02 Jun 2020

Reviewer's report:

The authors addressed all issues that I raised and made a comprehensive improvement of the manuscript. This paper might be acceptable for publication in BMC complementary Medicine and Therapies, provided that the authors made a minor revision regarding the following comment:

1. In abstract, what is OD, BD, eGFR, and hsCRP? It need to reduce some abbreviations in abstract.
2. In page 6, line 125, Group B - 1 identical placebo capsule taken in the evening after food orally. But, Group A and C - 2 identical placebo capsule taken in the evening after food orally. Check the amount of capsules taken in the evening (1 or 2). And Group A - is it correct to take it once a day?
3. In overall manuscript, there are some unnecessary abbreviations (for example, OD, BD, ADR, ED, and MDRD et al). It need to reduce some abbreviations.
4. In page 7, line 163, what is RI?
5. Authors mentioned that none of the product showed effect on platelet aggregation. What are the methods and results for platelet aggregation test using ADP? Authors should be explained in detail.
6. In page 14, what is XO? Authors should be explained it.
7. In page 17, delete some following sentences. Competing Interest: We acknowledge Natreon, Inc., USA, for …Funding: The design of the study, collection, analysis, and interpretation of data…
8. In table 1, what is BID? BD?

Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.

Yes

Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.

Yes

Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.

Yes

**Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?**

If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

I am able to assess the statistics

**Quality of written English**

Please indicate the quality of language in the manuscript:

Acceptable

**Declaration of competing interests**

Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

I declare that I have no competing interests'

**Reviewer Publication Consent.** I agree for my report to be made available under an Open Access Creative Commons CC-BY License (http://creativecommons.org/licenses/by/4.0) if this manuscript is accepted for publication. Any comments that I do not wish to be included in the published report have been included as confidential comments to the editor, which will not be published. If you are not happy for us to publish this report, please contact the editorial office before completing
the review. If you wish, you can include your name in your published report. Please note you must decide whether to include your name at the start of the process and confirm this decision whenever prompted. If you change your decision later, we will not be able to publish your name.

I agree to the terms of the CC-BY 4.0 license; please do not publish my name with my report. (default)